Morria Biopharmaceuticals Plc. is a private biopharmaceutical company focused on the development of novel, non-steroidal, anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs). These unique drugs target the PLA2 enzyme family, a sought-after pathway in the inflammation process upstream of current competitors. Morria is targeting several inflammatory diseases including eczema, hay-fever, Crohn’s disease, cystic fibrosis and inflammation of the eye. The total markets for these is in excess of $30bn.